Novavax - Vergessene Aktie feiert ein Comeback. Gute Chancen dank aktueller Nachrichtenlage (Seite 2128)
eröffnet am 25.04.09 09:22:26 von
neuester Beitrag 26.04.24 23:20:55 von
neuester Beitrag 26.04.24 23:20:55 von
Beiträge: 22.815
ID: 1.149.910
ID: 1.149.910
Aufrufe heute: 68
Gesamt: 1.231.783
Gesamt: 1.231.783
Aktive User: 0
ISIN: US6700024010 · WKN: A2PKMZ · Symbol: NVV1
3,8085
EUR
+3,58 %
+0,1315 EUR
Letzter Kurs 26.04.24 Tradegate
Neuigkeiten
20.04.24 · Felix Haupt Anzeige |
16.04.24 · Sharedeals |
18.03.24 · wallstreetONLINE Redaktion |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,9000 | +59,66 | |
| 0,5922 | +44,44 | |
| 6,8660 | +44,27 | |
| 11,690 | +40,84 | |
| 0,7000 | +36,69 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,6900 | -14,50 | |
| 2,8150 | -15,21 | |
| 7,6100 | -17,20 | |
| 1,6100 | -18,27 | |
| 2,1200 | -21,77 |
Beitrag zu dieser Diskussion schreiben
Feedback
Serum Institute Selects ABEC for Large-Scale, Single-Use COVID-19 Vaccine Manufacturing
ABEC’s Custom Single Run (CSR®) technology to support production of ~1 billion doses of Novavax COVID-19 vaccine
September 30, 2020 09:17 AM Eastern Daylight Time
BETHLEHEM, Pa.--(BUSINESS WIRE)--ABEC, a leading global provider of integrated solutions and services for biopharmaceutical manufacturing, today announced it is supporting Serum Institute of India Pvt. Ltd. (SIIPL) in Pune, India by delivering six 4,000L CSR bioreactors for the manufacturing of Novavax’ COVID-19 vaccine candidate, NVX‑CoV2373. Serum Institute, the world’s largest vaccine manufacturer by number of doses, will utilize ABEC’s single-use technologies to advance a global supply of NVX‑CoV2373 throughout India and low- and middle-income countries.
https://www.businesswire.com/news/home/20200930005056/en/Ser…
ABEC’s Custom Single Run (CSR®) technology to support production of ~1 billion doses of Novavax COVID-19 vaccine
September 30, 2020 09:17 AM Eastern Daylight Time
BETHLEHEM, Pa.--(BUSINESS WIRE)--ABEC, a leading global provider of integrated solutions and services for biopharmaceutical manufacturing, today announced it is supporting Serum Institute of India Pvt. Ltd. (SIIPL) in Pune, India by delivering six 4,000L CSR bioreactors for the manufacturing of Novavax’ COVID-19 vaccine candidate, NVX‑CoV2373. Serum Institute, the world’s largest vaccine manufacturer by number of doses, will utilize ABEC’s single-use technologies to advance a global supply of NVX‑CoV2373 throughout India and low- and middle-income countries.
https://www.businesswire.com/news/home/20200930005056/en/Ser…
📢 News nachbörslich
🎵
Novavax initiates late-stage coronavirus vaccine trials
The local biotech has initiated its first phase 3 trial in the United Kingdom
https://www.bizjournals.com/washington/news/2020/09/24/novav…
🎵
Novavax Impfstoffproduktion in Spanien
https://thecorner.eu/spain-economy/novavax-will-manufacture-…
US biotech company Novavax has signed an agreement to carry out the industrial production of its vaccine for Europe in Spain, once it becomes available, with Spanish pharmaceutical Zendal (through its subsidiary Biofabri).
Specifically, the Galician-based firm will be responsible for the production of the vaccine designed by Maryland-based Novavax for the European Union. The clinical trials are currently in Phase 2 and Phase 3 is expected to begin at the end of the third quarter 2020.
The Spanish Agency of Medicines and Health Products (AEMPS), dependent on the Ministry of Health, has affirmed that this fact is an “important” boost for Spain’s pharmaceutical industry.
Novavax is establishing a network of agreements to be able to manufacture its vaccine in the event it obtains marketing authorisation.
This announcement comes on top of the one from Spain’s Ministry of Health in July, related to the Spanish pharmaceutical company Rovi. It said Rovi will provide filling and finishing capacity for vials of the US firm Moderna’s vaccine. The latter wants to supply markets outside the United States starting in 2021.
https://thecorner.eu/spain-economy/novavax-will-manufacture-…
US biotech company Novavax has signed an agreement to carry out the industrial production of its vaccine for Europe in Spain, once it becomes available, with Spanish pharmaceutical Zendal (through its subsidiary Biofabri).
Specifically, the Galician-based firm will be responsible for the production of the vaccine designed by Maryland-based Novavax for the European Union. The clinical trials are currently in Phase 2 and Phase 3 is expected to begin at the end of the third quarter 2020.
The Spanish Agency of Medicines and Health Products (AEMPS), dependent on the Ministry of Health, has affirmed that this fact is an “important” boost for Spain’s pharmaceutical industry.
Novavax is establishing a network of agreements to be able to manufacture its vaccine in the event it obtains marketing authorisation.
This announcement comes on top of the one from Spain’s Ministry of Health in July, related to the Spanish pharmaceutical company Rovi. It said Rovi will provide filling and finishing capacity for vials of the US firm Moderna’s vaccine. The latter wants to supply markets outside the United States starting in 2021.
kenne dich zwar nicht, aber du könntest recht haben! vielleicht auch meehhrr! we will see!
Ich will ja nichts sagen, aber im Oktober könnte das AH angegriffen werden, wenn alles nach Plan läuft
Trading Spotlight
noch fragen! keine!
Ein galizisches Unternehmen wird für Europa den Impfstoff gegen Covid-19 des amerikanischen Unternehmens Novavax herstellen
Der biopharmazeutische Konzern Zendal wurde über seine Tochtergesellschaft Biofabri vom amerikanischen Pharmaunternehmen Novavax für die industrielle Herstellung seines Impfstoffs gegen Covid-19 in der Europäischen Union ausgewählt. Dies geht aus einer zwischen den beiden Unternehmen unterzeichneten Vereinbarung hervor.
Studien zum Impfstoff des amerikanischen Pharmaunternehmens mit Sitz in Meryland befinden sich derzeit in Phase 2 , obwohl davon ausgegangen wird, dass Phase 3 Ende des dritten Quartals 2020 beginnen könnte.
https://www.niusdiario.es/sociedad/compania-gallega-zendal-p…
Der biopharmazeutische Konzern Zendal wurde über seine Tochtergesellschaft Biofabri vom amerikanischen Pharmaunternehmen Novavax für die industrielle Herstellung seines Impfstoffs gegen Covid-19 in der Europäischen Union ausgewählt. Dies geht aus einer zwischen den beiden Unternehmen unterzeichneten Vereinbarung hervor.
Studien zum Impfstoff des amerikanischen Pharmaunternehmens mit Sitz in Meryland befinden sich derzeit in Phase 2 , obwohl davon ausgegangen wird, dass Phase 3 Ende des dritten Quartals 2020 beginnen könnte.
https://www.niusdiario.es/sociedad/compania-gallega-zendal-p…
Novavax Announces COVID-19 Vaccine Manufacturing Agreement with Serum Institute of India, Increasing Novavax’ Global Production Capacity to Over 2 Billion Doses Annually
Sep 15, 2020 at 7:00 AM EDT
GAITHERSBURG, Md., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced an amendment to its existing agreement with Serum Institute of India Private Limited (SIIPL) under which SIIPL will also manufacture the antigen component of NVX‑CoV2373, Novavax’ COVID‑19 vaccine candidate. With this agreement, Novavax increases its manufacturing capacity of NVX-CoV2373 to over two billion doses annually, when all planned capacity has been brought online by mid-2021. NVX‑CoV2373 is a stable, prefusion protein made using Novavax’ recombinant protein nanoparticle technology and includes Novavax’ proprietary Matrix‑M™ adjuvant.
“Today’s agreement with Serum Institute enhances Novavax’ commitment to equitable global delivery of our COVID-19 vaccine. With this arrangement, we have now put in place a global supply chain that includes the recently acquired Praha Vaccines and partnerships with leading biologics manufacturers, enabling production on three continents,” said Stanley C. Erck, President and Chief Executive Officer of Novavax. “We continue to work with extraordinary urgency to develop our vaccine, now in Phase 2 clinical trials, and for which we anticipate starting Phase 3 efficacy trials around the world in the coming weeks.”
https://ir.novavax.com/news-releases/news-release-details/no…
Sep 15, 2020 at 7:00 AM EDT
GAITHERSBURG, Md., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced an amendment to its existing agreement with Serum Institute of India Private Limited (SIIPL) under which SIIPL will also manufacture the antigen component of NVX‑CoV2373, Novavax’ COVID‑19 vaccine candidate. With this agreement, Novavax increases its manufacturing capacity of NVX-CoV2373 to over two billion doses annually, when all planned capacity has been brought online by mid-2021. NVX‑CoV2373 is a stable, prefusion protein made using Novavax’ recombinant protein nanoparticle technology and includes Novavax’ proprietary Matrix‑M™ adjuvant.
“Today’s agreement with Serum Institute enhances Novavax’ commitment to equitable global delivery of our COVID-19 vaccine. With this arrangement, we have now put in place a global supply chain that includes the recently acquired Praha Vaccines and partnerships with leading biologics manufacturers, enabling production on three continents,” said Stanley C. Erck, President and Chief Executive Officer of Novavax. “We continue to work with extraordinary urgency to develop our vaccine, now in Phase 2 clinical trials, and for which we anticipate starting Phase 3 efficacy trials around the world in the coming weeks.”
https://ir.novavax.com/news-releases/news-release-details/no…
Falls jemand die Studienergebnise der Phase1/2 lesen möchte:
https://pubmed.ncbi.nlm.nih.gov/32877576/
https://pubmed.ncbi.nlm.nih.gov/32877576/
Durchsuchen
16.04.24 · Sharedeals · Novavax |
18.03.24 · wallstreetONLINE Redaktion · Guess? |
03.03.24 · wO Chartvergleich · Allianz |
29.02.24 · Sharedeals · Novavax |
28.02.24 · BörsenNEWS.de · Novavax |
28.02.24 · wallstreetONLINE Redaktion · Novavax |
25.02.24 · wO Chartvergleich · ENCAVIS |
23.02.24 · PR Newswire (dt.) · Novavax |
22.02.24 · wallstreetONLINE Redaktion · Novavax |
21.02.24 · wO Chartvergleich · Dow Jones |